Cannabis for endometriosis: what the evidence can and cannot say

Share This Story

Last updated: 28 June 2026.

Endometriosis can be brutal. Pain, fatigue, fertility worries, sex pain, bowel or bladder symptoms, and the time it can take to get answers all add up. It is completely understandable that some patients start asking whether medical cannabis could have a role, especially when standard options have not worked well enough or have caused problems.

MCPH can say that plainly because this is a patient-led site. The point is not to sell cannabis as the answer. The point is to explain why patients ask the question and what the evidence can and cannot support.

The practical answer is this: cannabis products should not be presented as a routine, proven treatment for endometriosis itself on current evidence. Separately, medical cannabis may still be a reasonable specialist-assessment conversation for some patients with long-term pain or related symptoms where other treatments have not worked well enough or have not been suitable.

What endometriosis is

Endometriosis is a condition where tissue similar to the lining of the womb grows elsewhere in the body. The NHS says it can have a big impact on life, and symptoms can include severe period pain, pelvic pain, pain during or after sex, pain when using the toilet, fatigue, difficulty getting pregnant, low mood and anxiety.

Treatment usually focuses on managing symptoms and may involve pain medicines, hormonal treatments, surgery, fertility support, and specialist endometriosis care.

There is currently no cure for endometriosis, but treatments can help manage symptoms.

Why some patients ask about medical cannabis

Patients usually ask about cannabis for practical reasons, not because they want hype.

They may have tried painkillers, hormonal treatments, surgery, lifestyle changes, pelvic-health support, or other approaches and still be struggling. Some treatments help one person and do not help another. Some cause side effects. Some are not suitable because of fertility plans, other conditions, or personal history.

That is the real-world context. It does not prove cannabis is right for the patient, but it does explain why the question comes up.

What the evidence can say

The honest version is that the evidence is still developing.

Some patients with endometriosis, gynaecological pain, or chronic pelvic pain report using cannabis and finding parts of it helpful. That matters because patient experience matters. But self-reported benefit is not the same as strong clinical proof.

Guidance in this area is cautious because there is not enough high-quality evidence to say cannabis products should be routinely recommended for endometriosis pain. That does not make the patient question silly. It means the conversation needs to be clinically framed.

A patient can say, “I have endometriosis, these treatments have not worked well enough, and I want to understand whether medical cannabis could be suitable.”

A good clinician still needs to look at the whole case.

How UK prescribing guidance fits

This is where patient reality and official guidance can sound like they are pulling in different directions.

NICE guidance is cautious on cannabis-based medicinal products for chronic pain. NHS England also says the evidence for cannabis-based products in pain is not sufficiently developed for routine use, even though individual patients may perceive benefit.

That does not mean a patient is wrong to ask. NHS England also makes clear there is no fixed legal list of indications for CBPMs. Prescribing is a clinical decision, based on the individual patient, the condition, other medicines, the evidence, safety, and whether other licensed medicines are suitable.

The GMC frame is similar: many CBPMs are unlicensed, and prescribing may be appropriate where a specialist doctor assesses the individual patient and concludes it is necessary for that patient’s specific needs.

So the MCPH position is not “medical cannabis treats endometriosis”. It is: the evidence is limited and official guidance is cautious, but a specialist assessment conversation may still be reasonable for some patients with persistent symptoms after other options have not worked well enough or have not been suitable.

What the evidence cannot say

MCPH should not claim that cannabis:

treats endometriosis itself
shrinks lesions
stops disease progression
replaces gynaecology care
is safer than opioids or hormones as a broad claim
works for everyone with pelvic pain
is suitable in pregnancy, breastfeeding, or fertility treatment without specialist advice

Those claims go beyond what a patient information page should say.

What a clinic may want to understand

If a patient with endometriosis asks a medical cannabis clinic for assessment, the clinic may want to understand:

the diagnosis and symptom pattern
what treatments have already been tried
what helped, what did not, and what caused side effects
current medicines, including pain medicines, hormones, antidepressants, sleep medicines, or supplements
mental health history and any previous adverse reaction to cannabis
pregnancy, breastfeeding, fertility plans, or upcoming surgery
whether the symptoms need further gynaecology review
what the patient is hoping to improve

The Summary Care Record may be a useful starting document if it shows the condition and recent treatments. Some patients may need extra clinic letters or specialist notes if the SCR does not show enough detail.

How to ask the question without overcomplicating it

A practical way to frame it is:

“I have endometriosis. I have tried these treatments. These are the symptoms still affecting my life. These are the side effects or problems I have had. I would like to know whether medical cannabis could be suitable for me.”

That is not pushing for a product. It is asking for a proper assessment.

Patients can also ask about forms, such as oil or flower, and practical preferences. Suitability, product choice, dose, monitoring, and risk factors sit with the prescriber.

When this is not the right route

Medical cannabis should not be used to avoid urgent care or proper investigation.

Patients should seek appropriate medical help if symptoms are new, severe, worsening, unusual, or involve heavy bleeding, fainting, chest symptoms, severe abdominal pain, pregnancy concerns, infection signs, or anything that feels unsafe.

If endometriosis symptoms are not controlled, or if diagnosis is uncertain, that also deserves proper NHS or specialist review. Medical cannabis assessment does not replace gynaecology care.

The MCPH view

Endometriosis is exactly the sort of condition where patients deserve better practical information. People living with chronic pelvic pain are often already doing the hard work: trying treatments, explaining symptoms, managing side effects, and trying to keep life moving.

Medical cannabis should not be hyped as a cure-all or magic answer. It also should not be dismissed in language that makes patients feel foolish for asking.

The honest middle is better: for some patients, it may be a reasonable clinical conversation after other treatments have not worked well enough or have not been suitable. The decision still belongs inside specialist assessment.

Useful next reads

Sources

MCPH Founder

Founder of MCPH. Medical Cannabis advocate since 2010. Cannabis Patient since 2023.

Cannabis for endometriosis: what the evidence can and cannot say